Also trades as: 4527.T (JPX) · $vol 20M
RPHCF OTC
Rohto Pharmaceutical Co.,Ltd.
1W: +0.0%
1M: -1.1%
3M: -1.1%
YTD: -9.0%
1Y: +inf%
3Y: -29.3%
5Y: -74.5%
$15.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$345.9B
+12.1% ▲
5Y CAGR: +13.8%
Gross Profit
$184.1B
+5.2% ▲
5Y CAGR: +186.7%
Operating Income
$41.0B
+5.2% ▲
5Y CAGR: +12.2%
Net Income
$34.5B
+11.2% ▲
5Y CAGR: +15.5%
EPS (Diluted)
$147.00
+8.5% ▲
5Y CAGR: +15.0%
EBITDA
$58.4B
+3.6% ▲
5Y CAGR: +14.3%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $199.6B | $238.7B | $270.8B | $308.6B | $345.9B |
| YoY Growth | +10.3% | +19.5% | +13.5% | +14.0% | +12.1% |
| Cost of Revenue | $703M | $779M | $113.6B | $133.7B | $161.8B |
| Gross Profit | $937M | $1.0B | $157.3B | $174.9B | $184.1B |
| Gross Margin | 0.5% | 0.4% | 58.1% | 56.7% | 53.2% |
| R&D Expenses | $72M | $84M | $13.4B | $14.9B | $13.8B |
| SG&A Expenses | $636M | $681M | $54.2B | $57.5B | $129.3B |
| Operating Expenses | $708M | $765M | $117.2B | $136.0B | $143.1B |
| Operating Income | $29.0B | $34.0B | $40.0B | $38.9B | $41.0B |
| Operating Margin | 14.5% | 14.2% | 14.8% | 12.6% | 11.8% |
| Interest Expense | $248M | $247M | $196M | $949M | $1.3B |
| Income Before Tax | $27.9B | $34.3B | $41.5B | $42.3B | $47.1B |
| Tax Expense | $6.7B | $7.9B | $10.1B | $11.4B | $12.5B |
| Net Income | $21.1B | $26.4B | $30.9B | $31.0B | $34.5B |
| Net Margin | 10.6% | 11.1% | 11.4% | 10.0% | 10.0% |
| EPS (Diluted) | $92.34 | $115.29 | $135.21 | $135.44 | $147.00 |
| EBITDA | $35.8B | $42.3B | $50.4B | $56.4B | $58.4B |
| Shares Outstanding | 229M | 229M | 229M | 229M | 235M |